Avadel Pharmaceuticals plc - ADR

+0.04 (+0.46%)
Earnings Announcements

Avadel Pharmaceuticals Reports Third Quarter Results

Published: 11/09/2022 15:30 GMT
Avadel Pharmaceuticals plc - ADR (AVDL) - Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results.
Q3 Loss per Share $0.33.
As of Sept 30, Had $26.4 Million of Convertible Debt That Matures in Feb 2023 and $117.4 Million That Matures in Oct 2023.
Cash, Cash Equivalents and Marketable Securities $106.5 Million As of Sept 30.
Q3 Earnings per Share View $-0.25 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.